Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Universita' Degli Studi Di Torino
Sponsor

Universita' Degli Studi Di Torino

Italy Regione Gonzole 10, 10043 Orbassano, Italy

About the sponsor

Multiple myeloma is a major area of interest, with studies spanning newly diagnosed disease in patients eligible for autologous stem cell transplantation and in older or transplant-ineligible populations.

  • Induction and maintenance strategies in newly diagnosed multiple myeloma
  • Treatment approaches for transplant-ineligible myeloma
  • Response and progression control in plasma cell disorders

Research activity in this area includes combinations built around proteasome inhibitors, immunomodulatory agents, and anti-CD38 therapy.

About Specializations

Universita' Degli Studi Di Torino runs clinical trials in conditions such as Plasma cell myeloma, Prostate cancer metastatic, Critical illness, Non-small cell lung cancer stage IV, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Prostate cancer metastatic

Recruiting

Study on Surgical Treatment with or without Apalutamide for Patients with High-Risk Prostate Cancer Eligible for Radical Prostatectomy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universita' Degli Studi Di Torino

Critical illness

Recruiting

Study on Preventing Cardiovascular Collapse in Critically Ill Adults Using Noradrenaline Tartrate During Tracheal Intubation

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Noradrenaline Tartrate
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer stage IV

Not yet recruiting

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Malignant pleural effusion

Not yet recruiting

Study of Hyperthermic Intrathoracic Chemotherapy with Cisplatin and Pleurectomy versus Standard Care in Patients with Malignant Pleural Effusion

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer stage IIIA+1

Not yet recruiting

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universita' Degli Studi Di Torino

Genitourinary tract neoplasm

Not yet recruiting

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer+1

Not yet recruiting

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Universita' Degli Studi Di Torino

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.